A Letter From Dr. Silver

January 11, 2010


Dear Colleagues:

I'd like to tell you that the randomized, double blind placebo control study using a JAK2 inhibitor for the treatment primary myelofibrosis in myelofibrosis related to PV is now open at Cornell. We would be happy to evaluate your patients for this medication. Results were presented at ASH this year. The Incyte drug does represent a significant advance for the treatment of some patients with massive splenomegaly. Please contact any of our leukemia doctors at 212-746-2098.

Best regard for the New Year.
Sincerely,
Richard T. Silver, MD
Past President NYSSMOH